HRTX Earnings & Financial Statements
Heron Therapeutics, Inc.
$0.36
-$0.03(-7.32%)
49
Overall
40
Value
50
Tech
57
Quality
Market Cap
$68.73M
Volume
2.09M
52W Range
$0.26 - $1.58
Target Price
$2.00
HRTX earnings and financial statements: Heron Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
HRTX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $154.90M | $144.28M | $127.04M | $107.67M | $86.35M |
| Cost of revenue | $41.35M | $38.65M | $65.11M | $54.87M | $46.02M |
| Operating income | -$2.54M | -$11.53M | -$110.61M | -$174.66M | -$217.83M |
| EBITDA | -$7.46M | -$2.58M | -$104.91M | -$190.35M | -$215.25M |
| Net income | -$20.20M | -$13.58M | -$110.56M | -$182.02M | -$220.68M |
| EPS (diluted) | $-0.12 | $-0.09 | $-0.80 | $-1.67 | $-2.24 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $255.88M | $233.15M | $222.51M | $250.95M | $305.71M |
| Total liabilities | $241.54M | $266.80M | $256.48M | $237.38M | $228.14M |
| Shareholders’ equity | $14.33M | -$33.65M | -$33.97M | $13.57M | $77.57M |
| Cash and equivalents | $28.65M | $25.80M | $28.68M | $15.36M | $90.54M |
| Long-term debt | $32.74M | $149.70M | $152.29M | $154.78M | $157.08M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$27.59M | -$22.53M | -$58.79M | -$146.91M | -$203.35M |
| Capital expenditure | -$219.0K | -$1.68M | -$1.54M | -$1.82M | -$3.02M |
| Free cash flow | -$27.91M | -$24.23M | -$60.33M | -$148.74M | -$206.38M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | HRTX | $0.36 | -7.3% | 2.09M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Heron Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW